VivoSim Labs, INC.VIVSEarnings & Financial Report
VivoSim Labs, Inc. is a preclinical biotechnology company that develops advanced human organ and tissue simulation platforms. Its products are used by pharmaceutical firms, contract research organizations, and academic institutions to evaluate drug safety, efficacy, and toxicity, reducing reliance on traditional animal testing in global life sciences research segments.
Revenue
$28.0K
Gross Profit
N/A
Operating Profit
$-2.6M
Net Profit
$-2.5M
Gross Margin
N/A
Operating Margin
-9410.7%
Net Margin
-9089.3%
YoY Growth
-6.7%
EPS
$-0.98
VivoSim Labs, INC. Q2 FY2026 Financial Summary
VivoSim Labs, INC. reported revenue of $28.0K (down 6.7% YoY) for Q2 FY2026, with a net profit of $-2.5M (up 0.2% YoY) (-9089.3% margin).
Key Financial Metrics
| Total Revenue | $28.0K |
|---|---|
| Net Profit | $-2.5M |
| Gross Margin | N/A |
| Operating Margin | -9410.7% |
| Report Period | Q2 FY2026 |
VivoSim Labs, INC. Annual Revenue by Year
VivoSim Labs, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $144.0K).
| Year | Annual Revenue |
|---|---|
| 2025 | $144.0K |
| 2023 | $370.0K |
VivoSim Labs, INC. Quarterly Revenue & Net Profit History
VivoSim Labs, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2026 | $26.0K | +8.3% | $-2.7M | -10350.0% |
| Q2 FY2026 | $28.0K | -6.7% | $-2.5M | -9089.3% |
| Q1 FY2026 | $37.0K | -5.1% | $-2.8M | -7683.8% |
| Q4 FY2025 | $51.0K | +75.9% | $6.9M | 13435.3% |
| Q3 FY2025 | $24.0K | +380.0% | $-3.4M | -14362.5% |
| Q2 FY2025 | $30.0K | — | $-2.5M | -8496.7% |
| Q1 FY2025 | $39.0K | -48.0% | $-3.3M | -8574.4% |
| Q4 FY2024 | $29.0K | -82.1% | $-3.0M | -10500.0% |
Income Statement
| Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $29000 | $39000 | $30000 | $24000 | $51000 | $37000 | $28000 | $26000 |
| YoY Growth | -82.1% | -48.0% | N/A | 380.0% | 75.9% | -5.1% | -6.7% | 8.3% |
Balance Sheet
| Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $6.3M | $9.5M | $6.8M | $3.8M | $14.7M | $12.0M | $9.7M | $7.0M |
| Liabilities | $2.7M | $2.8M | $3.1M | $3.5M | $4.2M | $2.4M | $2.6M | $2.5M |
| Equity | $3.6M | $6.7M | $3.7M | $364000 | $10.5M | $9.5M | $7.1M | $4.4M |
Cash Flow
| Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-2.7M | $-3.0M | $-2.6M | $-1.8M | $-2.0M | $-3.9M | $-2.4M | $-2.3M |